EpiVax is an American biotechnology company based in Rhode Island. [1] The company was founded in 1998 by Anne Searls De Groot, who serves as its CEO and CSO. [2] EpiVax holds the exclusive license to the EpiMatrix vaccine design technology. [3] [2] In 2020 it developed a COVID-19 vaccine, EPV-CoV19, in partnership with the University of Georgia and Immunomic Therapeutics. [4] [5] [6]
EpiVax is an American biotechnology company based in Rhode Island. [1] The company was founded in 1998 by Anne Searls De Groot, who serves as its CEO and CSO. [2] EpiVax holds the exclusive license to the EpiMatrix vaccine design technology. [3] [2] In 2020 it developed a COVID-19 vaccine, EPV-CoV19, in partnership with the University of Georgia and Immunomic Therapeutics. [4] [5] [6]